WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	91.24B +6.9%
Revenue (ttm)	8.02B +36.5%
Net Income	1.79B +17.1%
EPS	1.33 +12.8%
Shares Out	1.27B
PE Ratio	54.23
Forward PE	32.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,735,636
Open	72.05
Previous Close	73.15
Day's Range	69.20 - 73.20
52-Week Range	43.50 - 85.60
Beta	-0.75
Analysts	Strong Buy
Price Target	93.31 (+29.51%)
Est. Earnings	Mar 23, 2027

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, m...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 3,628
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.

Financial numbers in CNY

Analyst Summary

According to 21 analysts, the average rating for 2268 stock is "Strong Buy." The 12-month stock price target is $93.31, which is an increase of 29.51% from the latest price.

Price Target

$93.31

(29.51% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error